Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

By P. Johnson, S. Qin, Joong-Won Park, R. Poon, J. Raoul, P. Philip, Chih-Hung Hsu, Tsung‐Hui Hu, J. Heo, Jianming Xu and 17 more. Journal of Clinical Oncology, 2013

698 citations recorded by the source corpus.

Subfields: Hepatology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/198aec17f19e78abd62888920a91c7caa002090e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. M. Kudo
2. A. Cheng
3. F. Piscaglia
4. B. Sangro

In Molecular Biology

1. N. Vasudev
2. Andrew R Reynolds
3. Rakesh K. Jain

Citations in the corpus

• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, methodology): “sorafenib received systemic and nonsystemic post-sorafenib treatments, respectively compared with 319 39% and 27% of patients receiving sorafenib in this study.(7) Continuous improvements in care for 320 unresectable HCC have been made, and multimodality therapies, including locoregional treatment 3”
• Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. (2015, methodology): “Patients Entered Onto Clinical Trials We had access to a data set including 1,132 patients receiving sorafenib for unresectable advanced HCC within the control groups of two international clinical trials.(17,18) Of the 1,028 patients with complete data, 96% were classified as C-P grade A.”
• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “In addition to sorafenib and regorafenib, a variety of molecular targeted agents have been thoroughly investigated, including sunitinib [589], brivanib [590, 591], linifanib [592], ramucirumab (angiogenesis inhibitors) [593], erlotinib (EGFR inhibitor) [594], and everolimus (mTOR inhibitor) [595].”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Metastatic 1st line Sorafenib versus placebo NCT00105443 [17] Improvement in PFS and OS Brivanib versus sorafenib BRISK-FL [145] OS non-inferiority end-point for brivanib versus sorafenib not met Metastatic 2nd line Brivanib versus placebo BRISK-PS [146] Improvement in PFS but not OS improvement in ”
• Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2018, background): “(10-11) In addition to the high concordance among monozygotic twins compared with dizygotic twins with PBC(5), the strong association with human leukocyte antigen alleles, which vary by ethnicity, supports a genetic cause of inherited risk.(12-20) Despite progress, only an estimated 15% of the varia”